We examined the expression of VSIR in BrMs and gliomas in the non-immune (CD45-) population as a comparison between primary and metastatic brain tumors as the Klemm study highlighted that there are differences between these tumors. This evidence concerns the gene PTPRC and central nervous system cancer.